These courses are intended for internal hospital staff.
This tumor board series consists of case presentations that are led by recognized multidisciplinary experts in the field of cutaneous oncology. Multidisciplinary tumor boards bring together health care professionals from multiple specialties to strategize about the best treatments for Cutaneous cancer cases. Please note that these tumor boards may only be accessed by qualified professionals directly associated with patient treatment. With the rapidly changing advances in the medical field, this is a forum that will provide clinical staff the opportunity to discuss and share new cutting-edge science, clinical, prognostic, biologic, radiologic, and treatment information for all who attend.
Anesthesiology, Diagnostic Radiology, Dermatology, Surgical Oncology, Medical Oncology, Plastic Surgeons, Internal Medicine, Family Medicine, Nurse Practitioners and Physician Assistants
- Analyze literature regarding the utility of molecular assays in skin cancer diagnosis and management
- Examine in-office and at-home technologies for skin cancer management
- Review data regarding disparities in skin cancer outcomes in skin of patients of color
- Review management strategies for cutaneous side-effects of immunotherapy
- Review of multidisciplinary care for cutaneous T-cell lymphoma
Ryan Weight, MD
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*
*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.
The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.